From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance

被引:588
作者
Litman, T
Druley, TE
Stein, WD
Bates, SE
机构
[1] Univ Copenhagen, Panum Inst 12633, Dept Med Physiol, DK-2200 Copenhagen N, Denmark
[2] Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA
[3] Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, Jerusalem, Israel
[4] NCI, Med Branch, NIH, Bethesda, MD 20892 USA
关键词
multidrug resistance; P-glycoprotein (MDR1); multidrug-resistance-associated protein (MRP); mitoxantrone resistance protein (MXR; BCRP; ABCP; ABCG2); ABC transporter; ATPase;
D O I
10.1007/PL00000912
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The ATP binding cassette (ABC) superfamily of membrane transporters is one of the largest protein classes known, and counts numerous proteins involved in the trafficking of biological molecules across cell membranes. The first known human ABC transporter was P-glycoprotein (P-gp), which confers multidrug resistance (MDR) to anticancer drugs. In recent years, we have obtained an increased understanding of the mechanism of action of P-gp as its ATPase activity, substrate specificity and pharmacokinetic interactions have been investigated. This review focuses on the functional characterization of P-gp, as well as other ABC transporters involved in MDR: the family of multidrug-resistance-associated proteins (MRP1-7), and the recently discovered ABC half-transporter MXR (also known as BCRP, ABCP and ABCG2). We describe recent progress in the analysis of protein structure-function relationships, and consider the conceptual problem of defining and identifying substrates and inhibitors of MDR. An in-depth discussion follows of how coupling of nucleotide hydrolysis to substrate transport takes place, and we propose a scheme for the mechanism of P-gp function. Finally, the clinical correlations, both for reversal of MDR in cancer and for drug delivery, are discussed.
引用
收藏
页码:931 / 959
页数:29
相关论文
共 234 条
[1]  
Allen JD, 2000, CANCER RES, V60, P5761
[2]  
Allen JD, 1999, CANCER RES, V59, P4237
[3]  
Allikmets R, 1998, CANCER RES, V58, P5337
[4]  
ALMQUIST KC, 1995, CANCER RES, V55, P102
[5]  
ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197
[6]  
ALSHAWI MK, 1994, J BIOL CHEM, V269, P8986
[7]   GENERATION OF A DRUG-RESISTANCE PROFILE BY QUANTITATION OF MDR-1/P-GLYCOPROTEIN IN THE CELL-LINES OF THE NATIONAL-CANCER-INSTITUTE ANTICANCER DRUG SCREEN [J].
ALVAREZ, M ;
PAULL, K ;
MONKS, A ;
HOSE, C ;
LEE, JS ;
WEINSTEIN, J ;
GREVER, M ;
BATES, S ;
FOJO, T .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (05) :2205-2214
[8]   Relation between the turnover number for vinblastine transport and for vinblastine-stimulated ATP hydrolysis by human P-glycoprotein [J].
Ambudkar, SV ;
Cardarelli, CO ;
Pashinsky, I ;
Stein, WD .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (34) :21160-21166
[9]   Biochemical, cellular, and pharmacological aspects of the multidrug transporter [J].
Ambudkar, SV ;
Dey, S ;
Hrycyna, CA ;
Ramachandra, M ;
Pastan, I ;
Gottesman, MM .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1999, 39 :361-398
[10]   PARTIAL-PURIFICATION AND RECONSTITUTION OF THE HUMAN MULTIDRUG-RESISTANCE PUMP - CHARACTERIZATION OF THE DRUG-STIMULATABLE ATP HYDROLYSIS [J].
AMBUDKAR, SV ;
LELONG, IH ;
ZHANG, JP ;
CARDARELLI, CO ;
GOTTESMAN, MM ;
PASTAN, I .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (18) :8472-8476